Метаболиты эстрогенов и их патогенетическая роль при раке предстательной железы (обзор)

Армаис Альбертович Камалов-; Зухра Шариповна Павлова; Андрей Владимирович Гострый; Дмитрий Александрович Охоботов; Родион Петрович Василевский

Метаболиты эстрогенов и их патогенетическая роль при раке предстательной железы (обзор)

Армаис Альбертович Камалов-¹, Зухра Шариповна Павлова², Андрей Владимирович Гострый³, Дмитрий Александрович Охоботов⁴, Родион Петрович Василевский⁵

научная статья Страницы: 5-13

¹ д.м.н., профессор, чл.-корр. РАН, директор Университетской клиники МГУ им. М.В. Ломоносова; зав. кафедрой урологии и андрологии, факультет фундаментальной медицины, МГУ им. М.В. Ломоносова
² к.м.н., врач-эндокринолог, Университетская клиника МГУ им. М.В.Ломоносова
³ врач общей практики, восстановительной, функциональной и антивозрастной медицины, Институт превентивной медицины (Москва)
⁴ к.м.н., врач-уролог, Университетская клиника МГУ им. М.В. Ломоносова
⁵ врач уролог-андролог, окружной уролог ЮЗАО, зав. отделением, ГБУЗ «ГП №134 ДЗМ»

Ключевые слова: эстрогены метаболиты эстрогенов эстрогенные рецепторы андрогены рак предстательной железы

Аннотация

Представлены данные, свидетельствующие о доминирующей роли метаболитов эстрогенов в сложном и многофакторном патогенезе рака предстательной железы.

Для цитирования

Камалов- А.А., Павлова З.Ш., Гострый А.В., Охоботов Д.А., Василевский Р.П. Метаболиты эстрогенов и их патогенетическая роль при раке предстательной железы (обзор) // Технологии живых систем. 2016. № 1. С. 5–13.

Список источников

Risbridger G.P., Ellem S.J., McPherson S.J. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling // Journal of Molecular Endocrinology. 2007. V. 39. P. 183-188.
Rohrmann S., Nelson W.G., Rifai N. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans //J. Clin. Endocrinol. Metab.2007. V. 92. № 7. Р. 2519-2525.
Дедов И.И., Мельниченко Г.А., Фадеев В.В. «Эндокинология», 2000.
James C. Roberts, M.D. FACC, FAARFM Estrogen Metabolismwithin the framework of Bioidentical Ovarian Hormone Replacement Therapy (HRT)// Methyl Cycle Nutrigenomics. 2012. Р. 33.
Nelles J.L., Hu Wen-Yang, Prins G.S. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab. Author manuscript; available in PMC. 2012. Mar. 1.2011 May; V. 6(3). P. 437-451.
Ellem S.J., Risbridger G.P. Aromatase and regulating the estrogen: androgen ratio in the prostate gland // Journal of Steroid Biochemistry and Molecular Biology. 2009. V. 188 (4-5). P. 246-251.
Prins G.S., Birch L., Couse J.F. et al. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies alpha ERKO and beta ERKO mice // Cancer. Res. 2001. V. 61. P. 6089-6097.
Nelson W.G., De Marzo A.M., De Weese T.L. et al. The role of inflammation in the pathogenesis of prostate cancer // J. Urol. 2004. V. 172. P. S6-SI1, discussion interfering with the dynamics of estrogen receptor regulated transcription.
Muti P., Bradlow H.L., Micheli A., Krogh V., Freudenheim J.L., Schunemann H.J., Stanulla M., Yang J., Sepkovic D.W., Trevisan M., Berrino F. Estrogen metabolism and risk of breast cancer: a prospective study of the : 16 alpha hydrox estrone ratio in premenopausal and postmenopausal women // Epidemiology. 2000. Nov. V. 11(6). P. 635-406.
ПримакА.В.Метаболизмэстрогеновуженщин. Общие представления и клиническая практика // Эстетическая медицина. 2006. Т. V. № 2.
Rogan E.G., Badawi A.F., Devanesan P.D., Meza J.L., Edney J.A., West W.W., Higginbotham S.M., Cavalieri E.L. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer // Carcinogenesis (England). 2003. Apr. V. 4. № 24. P. 697-702.
Liehr J.G., Ricci M.J. 4-Hydroxylation of estrogens as marker of human mammary tumors // Proc. Natl. Acad. Sci. USA. 1996. Apr. 16. V. 93. № 8. P. 3294-3296.
Utsunomiya H., Ito K., Suzuki T., Kitamura T., Kaneko C., Nakata T., Niikura H., Okamura K., Yaegashi N., Sasano H. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma // Clin. Cancer. Res. Sep. 1 2004. № 10 (17). P. 5850-5656.
Guillemette C., Belanger A., Lepine J. Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview // Breast. Cancer. Res. 2004. V. 6. № 6. P. 246-254.
Genova Diagnostics·A.L. Peace-Brewer, D(ABMLI), Lab. Director CLIA Lic. № 34D0655571. Medicare Lic. № 34-8475.
Bradlow H.L., Davis D.L., Lin G,. Sepkovich D., Tiwari R. Effects of pesticides on the ratio of 16/2-hydroxyestrone: a biologic marker of breast cancer risk // Environ Health Perspect. 1995. V. 103. (Suppl.7). Р. 147-150.
Bradlow H.L., Davis D.L., Lin G. et al. Effects of pesticides on the ratio of 16α/2- hydroxyestrone: a biological marker of breast cancer risk // Environ Health Perspect. 1995. V.103 (Suppl 7). P. 147-150.
Teas J.,Cunningham J.E.,Fowke J.H.,Nitcheva D.,Kanwat C.P.,Boulware R.J.,Sepkovic D.W.,Hurley T.G.,Hebert J.R. Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina // Cancer Detect Prev.2005.V. 29.№ 6. P. 494-500.
Muti P.,Westerlind K.,Wu T.,Grimaldi T.,De Berry J. 3rd,Schünemann H.,Freudenheim J.L.,Hill H.,Carruba G.,Bradlow L. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States // Cancer Causes Control.2002. Dec. 13(10). P. 947-955.
Barba M.1.,Yang L.,Schünemann H.J.,Sperati F.,Grioni S.,Stranges S.,Westerlind K.C.,Blandino G.,Gallucci M.,Lauria R.,Malorni L.,Muti P. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis //J. Exp. Clin. Cancer. Res.2009 Oct. 8. № 8. P. 135. doi: 10.1186. P. 1756-9966-28-135.
Santen R.J., Petroni G.R., Fisch M.J., Myers C.E., Theodorescu D., Cohen R.B. Use of the aromatase inhibitor anastrosole in the treatment of patients with advanced prostate carcinoma // Cancer. 2001. V. 92. P. 2095-2101.
Kruit W.H., Stoter G., Klijn J.G. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate specific antigen response in metabolic prostate cancer refractory to standard endocrine therapy // Anticancer Drugs. 2004. V. 15. P. 843-847.
АшрафянЛ.А.,КиселёвВ.И.Опухоли репродуктивных органов (этиология и патогенез). М. 2007.
Ioannides C. Effect of diet and nutrition on the expression of cytochromes P450. Xenobiotica 1999. V. 29(2). P. 109-154.
Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations // Scand. J. Clin. Lab. Invest. 1990. V. 50(S201). P. 3-23.
Cavalieri E.,Rogan E.G. The molecular etiology and prevention of estrogen-initiated cancers: Ockham\'s Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity // Mol. Aspects. Med. 2014. Apr; V. 36. P. 1-55. doi: 10.1016/j.mam.2013.08.002. Epub 2013 Aug 30.
Cavalieri E.L.,Rogan E.G. Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer // J. Steroid. Biochem. Mol. Biol.2011. V. 125(3-5). P. 169-80. doi: 10.1016/j.jsbmb. 2011.03.008. E. pub 2011. Mar. 21.
Yang L.,Gaikwad N.W.,Meza J.,Cavalieri E.L.,Muti P.,Trock B.,Rogan E.G.Novel biomarkers for risk of prostate cancer: results from a case-control study // Prostate.2009. Jan. 1. V. 69(1). P. 41-48. doi: 10.1002/ pros.20850.
Zhu X., Leav I., Leung Y.K., Wu M., Liu Q., Gao Y., McNeal J.E., Ho S.M. Dynamic regulation of estrogen receptor β-expression by DNA methylation during prostate cancer development and metastasis // American Journal of Pathology. 2009. V. 164. P. 2003-2012.
Шварц В.Я. Воспаление жировой ткани(часть 1). Морфологические и функциональные проявления // Проблемы эндокринологии. 2009. Т.55. №4. С.44-49.
Шварц В.Я. Жировая ткань, как эндокринологический орган // Проблемы эндокринологии. 2009. Т.55. №1. С.38-44.
Kunsch C., Medford R.M. Oxidative stress as a regulation of gene expression in the vasculature // Cire. Res. 1999. V. 85. P. 753-766.

[1] Risbridger G.P., Ellem S.J., McPherson S.J. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling // Journal of Molecular Endocrinology. 2007. V. 39. P. 183-188.

[2] Rohrmann S., Nelson W.G., Rifai N. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans //J. Clin. Endocrinol. Metab.2007. V. 92. № 7. Р. 2519-2525.

[3] Дедов И.И., Мельниченко Г.А., Фадеев В.В. «Эндокинология», 2000.

[4] James C. Roberts, M.D. FACC, FAARFM Estrogen Metabolismwithin the framework of Bioidentical Ovarian Hormone Replacement Therapy (HRT)// Methyl Cycle Nutrigenomics. 2012. Р. 33.

[5] Nelles J.L., Hu Wen-Yang, Prins G.S. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab. Author manuscript; available in PMC. 2012. Mar. 1.2011 May; V. 6(3). P. 437-451.

[6] Ellem S.J., Risbridger G.P. Aromatase and regulating the estrogen: androgen ratio in the prostate gland // Journal of Steroid Biochemistry and Molecular Biology. 2009. V. 188 (4-5). P. 246-251.

[7] Prins G.S., Birch L., Couse J.F. et al. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies alpha ERKO and beta ERKO mice // Cancer. Res. 2001. V. 61. P. 6089-6097.

[8] Nelson W.G., De Marzo A.M., De Weese T.L. et al. The role of inflammation in the pathogenesis of prostate cancer // J. Urol. 2004. V. 172. P. S6-SI1, discussion interfering with the dynamics of estrogen receptor regulated transcription.

[9] Muti P., Bradlow H.L., Micheli A., Krogh V., Freudenheim J.L., Schunemann H.J., Stanulla M., Yang J., Sepkovic D.W., Trevisan M., Berrino F. Estrogen metabolism and risk of breast cancer: a prospective study of the : 16 alpha hydrox estrone ratio in premenopausal and postmenopausal women // Epidemiology. 2000. Nov. V. 11(6). P. 635-406.

[10] ПримакА.В.Метаболизмэстрогеновуженщин. Общие представления и клиническая практика // Эстетическая медицина. 2006. Т. V. № 2.

[11] Rogan E.G., Badawi A.F., Devanesan P.D., Meza J.L., Edney J.A., West W.W., Higginbotham S.M., Cavalieri E.L. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer // Carcinogenesis (England). 2003. Apr. V. 4. № 24. P. 697-702.

[12] Liehr J.G., Ricci M.J. 4-Hydroxylation of estrogens as marker of human mammary tumors // Proc. Natl. Acad. Sci. USA. 1996. Apr. 16. V. 93. № 8. P. 3294-3296.

[13] Utsunomiya H., Ito K., Suzuki T., Kitamura T., Kaneko C., Nakata T., Niikura H., Okamura K., Yaegashi N., Sasano H. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma // Clin. Cancer. Res. Sep. 1 2004. № 10 (17). P. 5850-5656.

[14] Guillemette C., Belanger A., Lepine J. Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview // Breast. Cancer. Res. 2004. V. 6. № 6. P. 246-254.

[15] Genova Diagnostics·A.L. Peace-Brewer, D(ABMLI), Lab. Director CLIA Lic. № 34D0655571. Medicare Lic. № 34-8475.

[16] Bradlow H.L., Davis D.L., Lin G,. Sepkovich D., Tiwari R. Effects of pesticides on the ratio of 16/2-hydroxyestrone: a biologic marker of breast cancer risk // Environ Health Perspect. 1995. V. 103. (Suppl.7). Р. 147-150.

[17] Bradlow H.L., Davis D.L., Lin G. et al. Effects of pesticides on the ratio of 16α/2- hydroxyestrone: a biological marker of breast cancer risk // Environ Health Perspect. 1995. V.103 (Suppl 7). P. 147-150.

[18] Teas J.,Cunningham J.E.,Fowke J.H.,Nitcheva D.,Kanwat C.P.,Boulware R.J.,Sepkovic D.W.,Hurley T.G.,Hebert J.R. Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina // Cancer Detect Prev.2005.V. 29.№ 6. P. 494-500.

[19] Muti P.,Westerlind K.,Wu T.,Grimaldi T.,De Berry J. 3rd,Schünemann H.,Freudenheim J.L.,Hill H.,Carruba G.,Bradlow L. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States // Cancer Causes Control.2002. Dec. 13(10). P. 947-955.

[20] Barba M.1.,Yang L.,Schünemann H.J.,Sperati F.,Grioni S.,Stranges S.,Westerlind K.C.,Blandino G.,Gallucci M.,Lauria R.,Malorni L.,Muti P. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis //J. Exp. Clin. Cancer. Res.2009 Oct. 8. № 8. P. 135. doi: 10.1186. P. 1756-9966-28-135.

[21] Santen R.J., Petroni G.R., Fisch M.J., Myers C.E., Theodorescu D., Cohen R.B. Use of the aromatase inhibitor anastrosole in the treatment of patients with advanced prostate carcinoma // Cancer. 2001. V. 92. P. 2095-2101.

[22] Kruit W.H., Stoter G., Klijn J.G. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate specific antigen response in metabolic prostate cancer refractory to standard endocrine therapy // Anticancer Drugs. 2004. V. 15. P. 843-847.

[23] АшрафянЛ.А.,КиселёвВ.И.Опухоли репродуктивных органов (этиология и патогенез). М. 2007.

[24] Ioannides C. Effect of diet and nutrition on the expression of cytochromes P450. Xenobiotica 1999. V. 29(2). P. 109-154.

[25] Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations // Scand. J. Clin. Lab. Invest. 1990. V. 50(S201). P. 3-23.

[26] Cavalieri E.,Rogan E.G. The molecular etiology and prevention of estrogen-initiated cancers: Ockham\'s Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity // Mol. Aspects. Med. 2014. Apr; V. 36. P. 1-55. doi: 10.1016/j.mam.2013.08.002. Epub 2013 Aug 30.

[27] Cavalieri E.L.,Rogan E.G. Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer // J. Steroid. Biochem. Mol. Biol.2011. V. 125(3-5). P. 169-80. doi: 10.1016/j.jsbmb. 2011.03.008. E. pub 2011. Mar. 21.

[28] Yang L.,Gaikwad N.W.,Meza J.,Cavalieri E.L.,Muti P.,Trock B.,Rogan E.G.Novel biomarkers for risk of prostate cancer: results from a case-control study // Prostate.2009. Jan. 1. V. 69(1). P. 41-48. doi: 10.1002/ pros.20850.

[29] Zhu X., Leav I., Leung Y.K., Wu M., Liu Q., Gao Y., McNeal J.E., Ho S.M. Dynamic regulation of estrogen receptor β-expression by DNA methylation during prostate cancer development and metastasis // American Journal of Pathology. 2009. V. 164. P. 2003-2012.

[30] Шварц В.Я. Воспаление жировой ткани(часть 1). Морфологические и функциональные проявления // Проблемы эндокринологии. 2009. Т.55. №4. С.44-49.

[31] Шварц В.Я. Жировая ткань, как эндокринологический орган // Проблемы эндокринологии. 2009. Т.55. №1. С.38-44.

[32] Kunsch C., Medford R.M. Oxidative stress as a regulation of gene expression in the vasculature // Cire. Res. 1999. V. 85. P. 753-766.

Аннотация

Для цитирования

Похожие статьи